盐酸缬更昔洛韦片疗效好吗？

As a systemic antiviral drug, Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced on August 11, 2010 that the U.S. Food and Drug Administration (FDA) approved valganciclovir hydrochloride tablets (valamciclovir hydrochloride) for the treatment of adult kidney transplant patients at high risk of cytomegalovirus (CMV) disease.

Is Valganciclovir Hydrochloride Tablets effective?

Approval of this indication is based on data that longer-term prophylactic treatment with valganciclovir hydrochloride tablets reduced the incidence of CMV disease in high-risk adult kidney transplant patients from 36.8% (for patients who received 100 days of treatment) to 16.8% (for patients who received 200 days of treatment one year after receiving a kidney transplant) (p <0.0001) 1.2 The overall safety of valganciclovir hydrochloride tablets does not change when prophylaxis is extended in high-risk renal transplant patients.

"Among the different risks that people face after kidney transplantation, CMV is one that can be prevented through preventive treatment with valganciclovir hydrochloride tablets," said researcher Atul Humar, MD, associate professor in the Department of Transplantation Infectious Diseases and Medicine at the University of Aberdeen. "Data now show that we can further reduce the risk of CMV infection by increasing the duration of preventive treatment from 100 to 200 days.

CMV is a leading cause of illness and disease in the first 6 months after transplantation. An estimated 50-80% of all adults are infected with the CMV virus, most commonly while the body is dormant throughout life. The virus can be activated when the immune system is weakened, such as after an organ transplant. CMV infection may cause complications of the lungs, kidneys, nervous system, liver, and gastrointestinal tract.

Hal Barron, executive vice president of global development and chief medical, said: "Despite advances in the management of CMV, research shows that more than one-third of patients still develop a CMV infection even after 100 days of prophylaxis. "The approval provides important information for physicians treating high-risk adult patients during the critical period after kidney transplantation."